Clinical Trials Directory

Trials / Completed

CompletedNCT02420730

Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
77 (actual)
Sponsor
Allergan · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This study will examine the safety, tolerability, and systemic pharmacokinetics of up to 3 different concentrations of AGN-232411 topical ophthalmic solution in healthy participants and participants with dry eye.

Conditions

Interventions

TypeNameDescription
DRUGAGN-232411AGN-232411 topical ophthalmic solution
DRUGAGN-232411 VehicleVehicle for AGN-232411 topical ophthalmic solution.

Timeline

Start date
2015-06-01
Primary completion
2016-03-01
Completion
2016-03-01
First posted
2015-04-20
Last updated
2016-07-14

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02420730. Inclusion in this directory is not an endorsement.